先聲藥業(02096.HK)與Vivoryon建立戰略區域許可合作伙伴關係
格隆匯6月29日丨先聲藥業(02096.HK)發佈公吿,2021年6月29日,公司已根據許可協議與Vivoryon Therapeutics N.V.(阿姆斯特丹證券交易所股份代號:VVY)(“Vivoryon”,一家專注於開發創新小分子藥物的臨牀階段生物科技公司)建立戰略區域許可合作伙伴關係,以在大中華區進行靶向毒性澱粉樣蛋白N3pE(pGlu-Abeta)藥物的開發及商業化。
協議授權公司區域特許以在大中華區開發及商業化兩個產品:varoglutamstat(PQ912),Vivoryon處於全球臨牀IIb期的靶向谷氨醯胺醯基環化酶(QPCT)的口服小分子抑制劑,直接作用於毒性澱粉蛋白N3pE;以及PBD-C06,Vivoryon臨牀前的單克隆N3pE抗體。
根據協議條款,Vivoryon將收取前期款項,且亦將在取得若干開發成果及銷售里程碑後獲得公司的付款,所有款項合計超過5.65億美元。同時,Vivoryon將有權收取雙位數的銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.